MRNA
Moderna, Inc.Healthcare · $76.4B market cap
Verdict
We can't put a fair value on MRNA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow MRNA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 1 sale worth $486K and 11 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
Klinger Shannon Thyme
Chief Legal Officer · 2026-09-04
Tax withholding
$849K
Klinger Shannon Thyme
Chief Legal Officer · 2026-09-04
Option exercise
11,797 shares
Mock James M
Chief Financial Officer · 2026-09-04
Tax withholding
$849K
Mock James M
Chief Financial Officer · 2026-09-04
Option exercise
11,797 shares
Hoge Stephen
President · 2026-09-01
Tax withholding
$630K
Show all 11 other filingsShow fewer
Hoge Stephen
President · 2026-09-01
Option exercise
9,283 shares
Mock James M
Chief Financial Officer · 2026-09-01
Tax withholding
$168K
Mock James M
Chief Financial Officer · 2026-09-01
Option exercise
2,475 shares
Klinger Shannon Thyme
Chief Legal Officer · 2026-09-01
Tax withholding
$147K
Klinger Shannon Thyme
Chief Legal Officer · 2026-09-01
Option exercise
2,166 shares
Klinger Shannon Thyme
Chief Legal Officer · 2026-09-01
Option exercise
$107K
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works